Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469203 | 0.84 | BCHE (0.41) | KCNH2TMEM97KMT2AMEN1BCHE | |
| SCHEMBL6470735 | 0.84 | VNN1 (0.43) | KMT2AEPHX2PPARGHDAC3HDAC1 | |
| SCHEMBL5042778 | 0.82 | TMEM97 (0.63) | EGFRKCNH2TMEM97KMT2AMEN1 | |
| SCHEMBL5131617 | 0.81 | BCHE (0.58) | KCNH2TMEM97KMT2AMEN1BCHE | |
| SCHEMBL6468962 | 0.80 | TMEM97 (0.48) | EGFRKCNH2TMEM97KMT2AMEN1 | |
| SCHEMBL5037248 | 0.79 | MEN1 (0.40) | KCNH2TMEM97KMT2AMEN1BCHE | |
| SCHEMBL6471113 | 0.78 | TMEM97 (0.44) | KCNH2TMEM97KMT2AMEN1BCHE | |
| SCHEMBL6468183 | 0.77 | POLB (0.40) | KCNH2TMEM97BCHEMAOB | |
| SCHEMBL5133519 | 0.76 | CPB2 (0.40) | EGFRKCNH2KMT2AMEN1BCHE | |
| SCHEMBL6471056 | 0.75 | NOS1 (0.46) | KMT2AMEN1BCHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | EGFR 1706/4885KCNH2 2412/4885TMEM97 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.